Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome

Area of Science:

• Neuroscience
• Cellular Biology
• Genetics

Background:

• Fragile X syndrome (FXS) is a genetic disorder characterized by intellectual disability and behavioral issues.
• The absence of fragile X mental retardation protein (FMRP) is linked to FXS, but its precise cellular role remains unclear.
• Immature dendritic spines in FXS suggest FMRP's involvement in synaptic structural protein regulation.

Purpose of the Study:

• To investigate the cellular defects in Fragile X syndrome (FXS) related to synaptic function.
• To examine the role of FMRP in the MAPK pathway, specifically ERK activation, following metabotropic glutamate receptor (mGluR) stimulation.
• To identify specific phosphatase activity in FXS synapses and its impact on ERK signaling.

Main Methods:

• Isolation of cortical synaptoneurosomes from wild-type (WT) and FMRP knockout (KO) mice.
• Stimulation of group I metabotropic glutamate receptors (mGluR1/5) to assess MAPK pathway activation.
• Analysis of ERK phosphorylation and phosphatase activity (PP2A, tyrosine phosphatase) in response to mGluR stimulation.
• Pharmacological inhibition of phosphatases to evaluate rescue of ERK activation.

Main Results:

• ERK dephosphorylation occurred rapidly in KO synaptoneurosomes upon mGluR1/5 stimulation, unlike WT mice.
• Overactivation of protein phosphatase 2A (PP2A) after mGluR1 and tyrosine phosphatase after mGluR5 was observed in KO synapses.
• Pretreatment with phosphatase blockers, including okadaic acid (PP2A inhibitor), restored normal ERK activation in KO synaptoneurosomes.

Conclusions:

• Aberrant phosphatase overactivation in synapses is a key cellular deficit in Fragile X syndrome (FXS).
• This phosphatase overactivation disrupts normal ERK signaling, impacting synaptic function.
• Targeting phosphatase activity may offer a therapeutic strategy for FXS, addressing deficits in synaptic translation, transcription, and receptor regulation.